Bayer Plans Staff Reductions at US Plant Producing Hemophilia Therapies
Bayer is planning staff reductions of approximately 227 employees at its biologics manufacturing plant in Berkeley, California, which recently began production of its newly approved hemophilia A therapy, Jivi (antihemophilic factor [recombinant]). The reductions are a result of a reorganization of the manufacturing of Bayer’s hemophilia factor VIII replacement therapies for more efficiency.
Bayer’s Berkeley site is responsible for producing all three of Bayer’s recombinant factor VIII therapies, including Jivi, Kovaltry antihemophilic actor (recombinant), and Kogenate FS antihemophilic factor (recombinant). Bayer says the cuts will not affect availability of any of its products.
The US Food and Drug Administration (FDA) approved Jivi in August 2018 for routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.